Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Panelists discuss the expanding array of treatment options for metastatic hormone receptor–positive breast cancer, ...

Researchers in France have developed an antibody that blocks AMH, reversing PCOS symptoms in mice and opening the door to future human trials.

ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

A team from the Institut Curie, Inserm, and CNRS[1] has uncovered a new molecular mechanism, previously unknown, linking ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led ...

Research carried out on mice has revealed how a hormone released by the intestine acts on the brain and helps regulate the ...

Many people have that I-need-a-hug feeling these days. Here are surprising ways to stimulate the release of the feel-good hormone oxytocin — without a hug.